Tavares Diego Freitas, Dos Santos Carla Garcia Rodrigues, Valiengo Leandro Da Costa Lane, Klein Izio, Borrione Lucas, Forte Pamela Marques, Brunoni Andre R, Moreno Ricardo Alberto
Department of Psychiatry, University of São Paulo, São Paulo, Brazil.
Front Psychiatry. 2020 May 15;11:435. doi: 10.3389/fpsyt.2020.00435. eCollection 2020.
Mixed-specifier mood disorders are probably a different subgroup in terms of response to treatment, socio-demographic parameters, course, and family history. Here we describe the rationale and design of a clinical trial aimed to test the efficacy, safety, and tolerability of a non-pharmacological treatment known as theta-burst stimulation (TBS) for treating the mixed depressive episodes of both bipolar (I or II), and unipolar depression.
The study is designed as a randomized, sham-controlled, double-blinded clinical trial evaluating TBS for the treatment of moderate or severe major depressive episodes with mixed features of patients receiving at least one first or second-line pharmacological treatment for depressive episodes without adequate response. Ninety adult (18 to 65 years old) patients will be enrolled and submitted to 6-week (comprising 5 consecutive days a week sessions for the first 3 weeks and then 2 days a week for a further 3 week) of inhibitory followed by excitatory TBS in dorsolateral prefrontal cortex. Participants will be assessed using clinical and neuropsychological tests before and after the intervention. The primary outcome is change in Montgomery-Åsberg Depression Scale (MADRS) score over time and across groups. Cognitive parameters will also be assessed with neuropsychological tests.
The clinical results will provide evidence about TBS as an adjunctive treatment for mixed depression treatment and neuropsychological parameters will contribute toward an improved understanding the effects of TBS in cognition.
Our results could introduce a novel therapeutic technique for mixed depressive episodes of both bipolar and unipolar disorders.
www.ClinicalTrials.gov, identifier NCT04123301; date of registration: 10/10/2019; URL: https://clinicaltrials.gov/ct2/show/NCT04123301?term=NCT04123301&rank=1.
混合特征型心境障碍在治疗反应、社会人口统计学参数、病程及家族史方面可能属于不同的亚组。在此,我们描述一项临床试验的基本原理和设计,该试验旨在测试一种名为θ波爆发刺激(TBS)的非药物治疗方法对双相(I型或II型)及单相抑郁混合性抑郁发作的疗效、安全性和耐受性。
本研究设计为一项随机、假刺激对照、双盲临床试验,评估TBS对中度或重度伴有混合特征的重度抑郁发作的治疗效果,这些患者接受过至少一种一线或二线治疗抑郁发作的药物治疗但反应欠佳。将招募90名成年(18至65岁)患者,接受为期6周(前3周每周连续5天治疗,后3周每周2天治疗)的背外侧前额叶皮质抑制性然后兴奋性TBS治疗。干预前后将使用临床和神经心理学测试对参与者进行评估。主要结局是蒙哥马利-阿斯伯格抑郁量表(MADRS)评分随时间和组间的变化。还将通过神经心理学测试评估认知参数。
临床结果将为TBS作为混合性抑郁治疗的辅助治疗提供证据,神经心理学参数将有助于更好地理解TBS对认知的影响。
我们的结果可能为双相和单相障碍的混合性抑郁发作引入一种新的治疗技术。